Litcius/Paper detail

Increase in drugs‐of‐abuse findings in post‐mortem toxicology due to COVID‐19 restrictions—First observations in Finland

Claudia Mariottini, Ilkka Ojanperä, Pirkko Kriikku

2020Drug Testing and Analysis18 citationsDOIOpen Access PDF

Abstract

A lot has been published on the anticipated effects of the current COVID-19 pandemic on users of illegal drugs. In this study, we present evidence-based data on such effects, namely, the increased number of drug findings in post-mortem investigations. All post-mortem toxicology cases positive for at least one of the following: buprenorphine, amphetamine or cannabis, were investigated in the first 8 months of the year 2020, and the monthly numbers were compared to those in the previous 5 years from 2015 to 2019. These substances served as indicator analytes that could reveal changes in the drug using population. Right after the government restrictions came into force in March 2020, the numbers of buprenorphine, amphetamine and cannabis findings increased. The increase was most noticeable for amphetamine and was evident in all age groups. Our findings indicate that the assumptions on the increased risk of drug-related harm (including death) have become reality. Reduced access to harm-reduction services seems to have increased the mortality among individuals that use buprenorphine, amphetamine or cannabis. Significant and prompt actions need to be taken in order to find new ways in helping this vulnerable group of people.

Topics & Concepts

CannabisBuprenorphineAmphetamineMedicineHarmCoronavirus disease 2019 (COVID-19)PopulationDrugPandemicHarm reductionEnvironmental healthPsychiatryForensic toxicologyToxicologyPsychologyPublic healthBiologyOpioidInternal medicinePathologyDiseaseInfectious disease (medical specialty)ChromatographyChemistryReceptorSocial psychologyDopamineCannabis and Cannabinoid ResearchForensic Toxicology and Drug AnalysisHIV, Drug Use, Sexual Risk